Cloretazine for the treatment of acute myeloid leukemia

被引：6

作者：

Vey, Norbert

Giles, Frank

机构：

[1] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France

[2] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2006年 / 6卷 / 03期

关键词：

acute myeloid leukemia; alkylating agents; cloretazine; elderly; induction chemotherapy; myelodysplastic syndrome;

D O I：

10.1586/14737140.6.3.321

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cloretazine is a new sulfonylhydrazine alkylating agent with antileukemic activity. Phase I studies have shown myelosuppression to be the dose limiting toxicity in both solid tumors and leukemias. A large Phase II study of single agent cloretazine (600 mg/m(2)) confirmed its activity in patients with relapsed acute myeloid leukemia, and in elderly patients with previously untreated acute myeloid leukemia or myelodysplastic syndrome. It also confirmed the limited nonhematological toxicity, even in elderly patients. Cloretazine can be safely combined with cytarabine, and this combination regimen is currently being tested in a large Phase III study in patients with relapsed acute myeloid leukemia. Cloretazine is a promising new antileukemic agent that may be incorporated into an intensive combination regimen.

引用

收藏

页码：321 / 328

页数：8

相关论文

共 66 条

[1]

BLAISE DP, 2005, CANCER, V21, P21

[2]

Bloomfield CD, 1998, CANCER RES, V58, P4173

[3] Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia [J].

Breems, DA ;

Löwenberg, B .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 130 (06) :825-833

[4] PREFERENTIAL ALKYLATION BY 1,3-BIS(2-CHLOROETHYL)-1-NITROSOUREA (BCNU) OF GUANINES WITH GUANINES AS NEIGHBORING BASES IN DNA [J].

BRISCOE, WT ;

DUARTE, SP .

BIOCHEMICAL PHARMACOLOGY, 1988, 37 (06) :1061-1066

[5] High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation [J].

Bug, G ;

Atta, J ;

Klein, SA ;

Hertenstein, B ;

Bergmann, L ;

Boehrer, S ;

Mousset, S ;

Hoelzer, D ;

Martin, H .

ANNALS OF HEMATOLOGY, 2005, 84 (11) :748-754

[6] Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial [J].

Burnett, AK ;

Goldstone, AH ;

Stevens, RMF ;

Hann, IM ;

Rees, JKH ;

Gray, RG ;

Wheatley, K .

LANCET, 1998, 351 (9104) :700-708

[7] The treatment of acute leukaemia [J].

Burnett, AK ;

Eden, OB .

LANCET, 1997, 349 (9047) :270-275

[8] Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission [J].

Cassileth, PA ;

Harrington, DP ;

Appelbaum, FR ;

Lazarus, HM ;

Rowe, JM ;

Paietta, E ;

Willman, C ;

Hurd, DD ;

Bennett, JM ;

Blume, KG ;

Head, DR ;

Wiernik, PH .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (23) :1649-1656

[9] Randomized comparison of double induction and timed-sequential induction to a "3+7" induction in adults with AML:: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study [J].

Castaigne, S ;

Chevret, S ;

Archimbaud, E ;

Fenaux, P ;

Bordessoule, D ;

Tilly, H ;

de Revel, T ;

Simon, M ;

Dupriez, B ;

Renoux, M ;

Janvier, M ;

Micléa, JM ;

Thomas, X ;

Bastard, C ;

Preudhomme, C ;

Bauters, F ;

Degos, L ;

Dombret, H .

BLOOD, 2004, 104 (08) :2467-2474

[10] Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia [J].

Cheson, BD ;

Bennett, JM ;

Kopecky, KJ ;

Büchner, T ;

Willman, CL ;

Estey, EH ;

Schiffer, CA ;

Döhner, H ;

Tallman, MS ;

Lister, TA ;

LoCocco, F ;

Willemze, R ;

Biondi, A ;

Hiddemann, W ;

Larson, RA ;

Löwenberg, B ;

Sanz, MA ;

Head, DR ;

Ohno, R ;

Bloomfield, CD .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4642-4649

← 1 2 3 4 5 6 7 →